Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 1/20 | 0.72 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | FABP1 | P07148 | 1/20 | 0.65 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.65 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.65 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2104423 | 0.98 | NR1H4 (0.70) | HPSENR1H4KMT2AMEN1FABP1 | |
| SCHEMBL9249052 | 0.92 | HPSE (0.84) | HPSENR1H4KMT2AMEN1KCNK3 | |
| SCHEMBL23513412 | 0.89 | NPC1 (0.74) | KMT2AMEN1KCNK3KCNK9POLB | |
| SCHEMBL12228168 | 0.88 | RAB9A (0.71) | KMT2AMEN1KCNK3KCNK9POLB | |
| SCHEMBL679144 | 0.88 | KMT2A (0.90) | HPSENR1H4KMT2AMEN1KCNK3 | |
| SCHEMBL2077842 | 0.87 | KCNK3 (0.81) | NR1H4KMT2AMEN1KCNK3KCNK9 | |
| SCHEMBL23070423 | 0.87 | KMT2A (0.80) | HPSENR1H4KMT2AMEN1KCNK3 | |
| Hydrochloric Acid SCHEMBL2106175 | 0.86 | KMT2A (0.87) | HPSENR1H4KMT2AMEN1KCNK3 | |
| SCHEMBL19303149 | 0.86 | KMT2A (0.59) | NR1H4KMT2AMEN1KCNK3KCNK9 | |
| Hydrochloric Acid SCHEMBL2105161 | 0.86 | KCNK3 (0.79) | NR1H4KMT2AMEN1KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2021042410-A1 | SELECTIVE BUTYRYLCHOLINESTERASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 中国药科大学 | 2021-03-11 | — | — | WO | disclosed |
| CN-110627767-B | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2020-08-25 | — | — | CN | disclosed |
| CN-110627767-A | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2019-12-31 | — | — | CN | disclosed |
| US-8163751-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20100183712-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-7713963-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-7179839-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-20 | — | — | US | disclosed |
| EP-1373191-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002064545-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | BCHE, ACHE, BACE1 | HPSE 1091/4885NR1H4 448/4885KMT2A 2073/4885 |
| US-20100183712-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | EDNRA, EDNRB, VEGFA | HPSE 3384/4885NR1H4 48/4885KMT2A 1586/4885 |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | EDNRA, VEGFA, EDNRB | HPSE 3471/4885NR1H4 45/4885KMT2A 1270/4885 |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | EDNRA, EDNRB, VEGFA | HPSE 3362/4885NR1H4 48/4885KMT2A 1581/4885 |
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | BCHE, ACHE, BACE1 | HPSE 1291/4885NR1H4 430/4885KMT2A 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.